DDInter130 DDInter1828
Atenolol is a cardioselective beta-blocker used in a variety of cardiovascular conditions. Sir James Black, a Scottish pharmacologist, pioneered the use of beta-blockers for the management of angina pectoris in 1958 for which he received the Nobel Prize. Beta-blockers quickly became popular in clinical use and where subsequently investigated for use in myocardial infarction, arrhythmias, and hypertension during the 1960s. Later they continued to be investigated for use in heart failure throughout the 1970-1980s. Atenolol itself was developed early on in this history by Alvogen Malta under the trade name Tenormin and received FDA approval in September, 1981.[label] Despite being one of the most widely prescribed beta blockers, evidence suggests atenolol may not significantly reduce mortality, and only modestly reduce the risk of cardiovascular disease in patients with hypertension.[A235850,A235855] A Cochrane review
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces.
Atenolol {u} (Compound) causes {v} (Side Effect) Agranulocytosis
Agranulocytosis {u} (Side Effect) is caused by {v} (Compound) Tolbutamide
Atenolol {u} (Compound) resembles {v} (Compound) Sotalol
Sotalol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Atenolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Atenolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Atenolol {u} (Compound) causes {v} (Side Effect) Agranulocytosis
Agranulocytosis {u} (Side Effect) is caused by {v} (Compound) Tolazamide
Tolazamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Atenolol {u} (Compound) resembles {v} (Compound) Sotalol
Sotalol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Atenolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Atenolol {u} (Compound) resembles {v} (Compound) Oxprenolol
Oxprenolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Atenolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Atenolol {u} (Compound) causes {v} (Side Effect) Agranulocytosis
Agranulocytosis {u} (Side Effect) is caused by {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Atenolol (Compound) causes Agranulocytosis (Side Effect) and Agranulocytosis (Side Effect) is caused by Tolbutamide (Compound)
Atenolol (Compound) resembles Sotalol (Compound) and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Atenolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Atenolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Atenolol (Compound) causes Agranulocytosis (Side Effect) and Agranulocytosis (Side Effect) is caused by Tolazamide (Compound) and Tolazamide (Compound) resembles Tolbutamide (Compound)
Atenolol (Compound) resembles Sotalol (Compound) and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Atenolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Atenolol (Compound) resembles Oxprenolol (Compound) and Oxprenolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Atenolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Atenolol (Compound) causes Agranulocytosis (Side Effect) and Agranulocytosis (Side Effect) is caused by Glipizide (Compound) and Glipizide (Compound) resembles Tolbutamide (Compound)